Standing Order
Eli Lilly and Company

Dashboard

Eli Lilly and Company

LLYNYSE

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$1.2T
Price$1,347.1152w $625.65 – $1,443.50
Conviction5/ 5
Revenue (TTM)$86.5B
Revenue growth YoY+45.5%
P/E (trailing)43.5
Gross margin83.6%
Operating margin46.1%
Net margin31.9%
52w price change+80.3%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 20
    Trial readoutClinicalTrials.gov

    Eli Lilly completes observational study NCT02951598 on healthcare use and costs in early Alzheimer's disease.

  • Nov 20
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 2 trial of Brenipatide for Major Depressive Disorder (NCT07928245, recruiting)

  • Nov 20
    Trial initiationClinicalTrials.gov

    Eli Lilly posts Phase 1 trial NCT07945314 for LY3839056 safety, tolerability and PK in healthy participants; status NOT_YET_RECRUITING.

  • Nov 20
    Trial readoutClinicalTrials.gov

    Phase 2 trial of tirzepatide in type 2 diabetes and obesity completed (NCT06037252).

  • Nov 19
    Trial readoutClinicalTrials.gov

    Eli Lilly completes Phase 1 study NCT07794592 comparing two administration methods of Olomorasib (LY3537982) in healthy participants.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1 trial NCT07915245 of LY4247147 for obesity/overweight in otherwise healthy participants; status recruiting.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1 trial NCT07339722 of LY4515100 in healthy participants (status: recruiting).

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07867340 of LY5625573 recruiting in healthy participants including Japanese/Chinese cohorts and those with inflammation.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07881887 of LY4167586 in obesity/overweight with or without T2D status recruiting.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07867327 of LY4515100 in healthy male participants now recruiting.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07881458 of EloraTZP in adults with obesity/overweight and type 2 diabetes begins recruiting.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07843459 of LY4560736 recruiting in healthy participants and Alzheimer's disease patients.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07945314 for LY3839056 in healthy participants, status not yet recruiting.

  • Nov 17
    OtherClinicalTrials.gov

    Phase 3 trial NCT06297603 (retatrutide in T2D with renal impairment) status updated to ACTIVE_NOT_RECRUITING.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Eli Lilly Phase 1 trial NCT07738614 of Eloralintide (LY3841136) in obesity/overweight updated to ACTIVE_NOT_RECRUITING.

  • Nov 17
    Trial readoutClinicalTrials.gov

    Phase 1 trial NCT07701083 of Eloralintide (LY3841136) in healthy participants completed.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Eli Lilly initiates Phase 1 trial NCT07787182 of LY4405094 in healthy participants and Alzheimer's disease patients.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 1 trial NCT07914738 of Lepodisiran (LY3819469) in high Lipoprotein(a) participants updated to recruiting status.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07881432 initiated for EloraTZP in obesity without Type 2 diabetes; status NOT_YET_RECRUITING.

  • Nov 17
    Trial readoutClinicalTrials.gov

    Completed Phase 1 study NCT07426380 of Eloralintide (LY3841136) in renal impairment and normal renal function participants.

Not financial advice — research and opinion only. Disclosures